Table 2.
Demographics and clinico-biological characteristics of the study population.
| Parameters | Control (n = 12) | HTN (n = 8) | T2D (n = 7) | HTN + T2D (n = 17) |
|---|---|---|---|---|
| Age, years | 56 [53–61] | 57 [54–61] | 58 [55–63] | 60 [58–66] |
| Male, n (%) | 5 (42%) | 4 (50%) | 2 (29%) | 11 (65%) |
| Body mass index (kg/m2) | 25 [23–26] | 25 [25–27] | 26 [25–30] | 31 [29–34] *,† |
| Smoking status, n | ||||
| Current/Past/Never | 1/4/7 | 0/0/8 | 1/1/5 | 0/9/8 |
| SBP, mmHg | 125 [119–133] | 140 [130–146] | 129 [127–140] | 135 [132–141] |
| DBP, mmHg | 77 [74–80] | 86 [82–90] | 81 [79–89] | 81 [72–91] |
| MBP, mmHg | 92 [91–95] | 106 [97–109] | 95 [95–105] | 100 [93–108] |
| Heart rate, bpm | 64 [60–71] | 58 [56–72] | 71 [61–81] | 72 [64–76] |
| LDL cholesterol, g/L | 1.48 [1.37–1.66] | 1.17 [1.07–1.24] | 1.25 [1.02–1.38] | 0.80 [0.62–1.04] * |
| HDL cholesterol, g/L | 0.59 [0.48–0.70] | 0.54 [0.47–0.69] | 0.70 [0.47–0.73] | 0.53 [0.40–0.61] |
| Triglycerides, g/L | 0.74 [0.70–0.91] | 0.88 [0.72–1.5] | 0.99 [0.81–1.42] | 1.00 [0.81–1.35] |
| Fasting glycemia, mg/dL | 1.00 [0.88–1.00] | 0.93 [0.90–1.01] | 1.40 [1.30–1.58] *,† | 1.35 [1.18–1.45] *,† |
| Insulinemia, pmol/L | 55 [37–78] | 71 [51–98] | 69 [62–78] | 90 [67–147] * |
| Hb1Ac, mmol/L | - | - | 6.9 [6.7–7.4] | 6.6 [6.2–6.9] |
| Creatinemia, µmol/L | 70 [61–73] | 75 [62–86] | 67 [61–73] | 65 [56–79] |
| Statins, n (%) | 1 (8%) | 2 (25%) | 2 (29%) | 13 (76%) * |
| Antihypertensive agents, n (%) | ||||
| ACEi/ARB | - | 7 (88%) | - | 12 (72%) |
| CCB | - | 2 (25%) | - | 11 (65%) |
| Beta-blokers | - | 0 (0%) | - | 2 (12%) |
| Diuretics | - | 0 (0%) | - | 7 (41%) |
| Hypoglycemic agents, n (%) | ||||
| Metformin | - | - | 7 (100%) | 14 (82%) |
| Sulfamides/glinides | - | - | 1 (14%) | 7 (41%) |
| DPP-4 inhibitors/GLP-1 agonists | - | - | 2 (29%) | 8 (47%) |
Data are expressed as median [interquartile] or n (%). ACEi: angiotensin-converting enzyme inhibitors; ACR: albumin-to-creatinine ratio; ARB: angiotensin type 1 receptor blockers; CCB: calcium channel blockers; DBP: diastolic blood pressure; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; HTN: hypertension; MBP: mean blood pressure; SBP: systolic blood pressure; T2D: type 2 diabetes. * p < 0.05 vs. Control † p < 0.05 vs. HTN.